Anti-Human APP/Amyloid beta Reference Antibody (BI 1034020)

Description: Anti-Human APP/Amyloid beta (BI 1034020) (BS10947) is a research-grade recombinant antibody targeting AICD-57. Produced in mammalian cells with native-like glycosylation.
Host species: Human
Isotype: IgG
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: AICD-57,A4,Beta-CTF,Proteasenexin-II,Gamma-CTF(50),ABPP,S-APP-beta,APP,Abeta40,Abeta42,AID(59),Amyloidintracellulardomain59,AID(57),S-APP-alpha,Gamma-CTF(59),Beta-secretaseC-terminalfragment,Amyloid-betaprecursorprotein,Amyloidprecursorprotein,Beta-APP42,PreA4,Alzheimerdiseaseamyloidprotein,APPI,PN-II,AICD-59,Alpha-secretaseC-terminalfragment,Amyloid-betaA4protein,Amyloidintracellulardomain57,CVAP,Amyloidintracellulardomain50,Beta-APP40,AD1,Cerebralvascularamyloidpeptide,AID(50),Alpha-CTF,Gamma-CTF(57),AICD-50
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: BI-1034020,BI1034020,BI1034020
Background: Amyloid-beta precursor protein (APP/Amyloid beta) is a ~86 kDa protein. Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(o) and JIP. APP is the therapeutic target of lecanemab (Leqembi)._x005f_x000D_ _x005f_x000D_
References:
1. Baumkötter, F. et al. (2014) The Journal of neuroscience : the official journal of the Society for Neuroscience 34, 11159-72. PMID: 25122912_x005f_x000D_ _x005f_x000D_
2. Satpute-Krishnan, P. et al. (2006) Proceedings of the National Academy of Sciences of the United States of America 103, 16532-7. PMID: 17062754_x005f_x000D_ _x005f_x000D_
3. Seamster, PE. et al. (2012) Physical biology 9, 055005. PMID: 23011729_x005f_x000D_
Note: For research use only. Not suitable for clinical or therapeutic use.